跳至主要内容
临床试验/NCT01438788
NCT01438788已完成2 期

Low Protein Diet to Correct Defective Autophagy in Patients With Collagen VI Related Myopathies

Istituto Ortopedico Rizzoli2 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2011年10月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
8
试验地点
2
主要终点
Reactivation of autophagy measured as a change in Beclin 1 as a marker of autophagy in muscle biopsy from baseline (Day 1) to Day 365

研究概览

简要总结

  • This is a 2 stage exploratory study with a 3-month observational phase on the natural course, followed by a 12-month, open-label, non-comparative, single-arm, phase II pilot study on the efficacy, safety and tolerability of a low-protein diet (LPD) in 8 adult patients with Bethlem myopathy (BM) and Ullrich congenital muscular dystrophy (UCMD).
  • Objective of this trial is to test the effect of a normocaloric LPD to reactivate autophagy in BM/UCMD patients. The primary end point of the study will be the change in muscle biopsy of Beclin 1, a marker of autophagy, at 1 year of LPD treatment when compared to baseline.
  • The rationale rests on our discoveries that (i) mitochondrial dysfunction mediated by inappropriate opening of the PTP plays a key role in collagen VI myopathies; (ii) defective autophagy with impaired removal of defective mitochondria amplifies the defect; and (iii) reactivation of autophagy with a low-protein diet or treatment with cyclosporine A, the mitochondrial PTP inhibitor, cured Co6a1-/- mice, hinting at a common target among all beneficial treatments - namely autophagy.
  • Specific aims of this project are to (i) study the modifications of clinical, nutritional and laboratory parameters in a cohort of patients with BM/UCMD during a 3-month observational period before starting the LPD treatment; (ii) assess the effect of a normocaloric LPD in correcting defective autophagy in muscle of patients; (iii) test if new non-invasive biomarkers of activation of autophagy examined in the blood are mirroring the effect of LPD in the muscle biopsy; (iv) assess the clinical efficacy and safety of the LPD with an innovative combination of complementary measures of the nutritional status in patients.
  • The anticipated output is defining and validating a therapeutic nutritional approach in autophagy upregulation for BM/UCMD.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males or females aged ≥18 years.
  • Women of childbearing age must have a negative pregnancy test and must use adequate contraception during the study.
  • Clinical and molecular diagnosis of Bethlem myopathy or Ullrich congenital muscular dystrophy.
  • No previous treatment with CsA within 6 months prior to the start of the study.
  • Willing and able to adhere to the study visit schedule and other protocol requirements.
  • Written informed consent signed.

排除标准

  • Current or history of liver or renal disease.
  • Pregnant or breast-feeding women.
  • Any serious internal medicine condition interfering with the study.

结局指标

主要结局

Reactivation of autophagy measured as a change in Beclin 1 as a marker of autophagy in muscle biopsy from baseline (Day 1) to Day 365

时间窗: one year

次要结局

  • Assess the safety of a LPD in patients with BM/UCMD . Nutritional parameters . Muscle mass . Muscle strength(one year)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验